GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
73 GF Score
Price ₹2,454.80
GF Value ₹2,630.11
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NSE:GLAXO
73GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,454.80 is trading 6.7% below its estimated GF Value™ of ₹2,630.11. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLAXO:

  • Short Ratio:
  • GF Value™: ₹2,630.11 vs. price of ₹2,454.80 (6.7% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score

Get the complete analysis for NSE:GLAXO

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,454.80
Price
₹2,630.11
GF Value